CellMax Life
The company believes the new results, from an initial prospective multisite trial, reflect what it can achieve in the larger cohort that it is now planning to recruit.
In Brief This Week: Biodesix, Avisa Diagnostics, Mount Sinai, Sophia Genetics, and More
News items for the in vitro diagnostics industry for the week of Aug. 23, 2021.
CellMax Life, Sebela Pharmaceuticals Sign Commercial Agreement for Colorectal Cancer Dx Test
CellMax also completed a Series C financing round to speed up development of itsFirstSight liquid biopsy test to detect colorectal cancer and precancer polyps.
Prospective Study Adds Evidence for CellMax Life Liquid Biopsy Utility in CRC Screening
Investigators reported on detection rates for cancers and precancers in a group of 350 individuals presenting for standard of care colonoscopy.
CellMax Life Highlights Liquid Biopsy Platform's Ability to Detect Pre-Cancer, Cancer
CellMax is developing and applying its CTC platform for early detection of colorectal cancer and more long term for breast and prostate cancer.
Jan 2, 2019